Humana Inc. (NYSE:HUM) is one of the Best 52-Week Low Stocks to Invest In, with fiscal Q4 2025 earnings expected on February 11, 2026. Revenue projections are around $32.08 billion, with an anticipated negative GAAP EPS of $4.08. Wall Street remains bullish on the company.

Analysts like David S Macdonald and Lance Wilkes have reiterated Hold and Buy ratings on Humana Inc. (NYSE:HUM) on January 27, with price targets ranging up to $344. The stock is under scrutiny ahead of its upcoming earnings release.

Piper Sandler released a research note on January 27 discussing the impact of the Medicare Advantage Advance Notice on healthcare stocks like Humana Inc. The notice is expected to directly affect revenue and profit margins for insurers in this sector.

Recent news reported a smaller than expected increase in 2027 Medicare Advantage rates proposed by the Trump administration, causing Humana Inc. (NYSE:HUM) shares to drop by over 24% and approach its 52-week lows. The company offers Medicare Advantage plans, Medicaid services, and specialty insurance products.

While Humana Inc. (NYSE:HUM) shows potential as an investment, some analysts believe AI stocks offer greater upside potential with lower downside risk. Investors can explore undervalued AI stocks poised to benefit from current trends in the market.

Read more at Yahoo Finance: Here’s What Wall Street Thinks About Humana Inc (HUM)